INVEST SECURITIES - Cellectis : Une semaine à rebondissements - ACHAT, OC : 34€ vs 38€
Après avoir annoncé le transfert de sa collaboration avec PFIZER à Allogène, la biotech française a lancé une offre au public aux Etats-Unis pour un montant de 175m$. Ces deux opérations stratégiques pour le groupe ont pour but d'accélérer le développement de la première vague de produit UCART19 mais aussi de la seconde vague de CAR-T allogéniques. Pour rappel, CELLECTIS affichait une trésorerie fin 2017 de 297m$ ce que nous considérions suffisant jusqu'à mi-2020. Nous ajustons notre OC à 34€ vs 38€ après mise à jour.Cellectis is a gene-editing company employing its core proprietary technologies to develop products in the field of immuno-oncology. UCART19 is Co.'s lead product. UCART19 is an engineered T-cell product which drives its ability to target and kill CD19-bearing cells, such as B-cell malignancies. Co. is also developing wholly-owned product candidates UCART123, UCARTCS1 and UCART38, which are in various stages of development. UCART 123, UCARTCS1 and UCART38 are engineered T-cell products that bear CARs that seek to kill cells expressing targets CD123, CS1 and CD38, respectively, which are found in other hematologic tumors, such as acute myeloid leukemia, or AML, and multiple myeloma, or MM.
Since 2006, Invest Securities has become one of the leading players in investment services for funds and managers, to whom we offer a global and personalised service. Our track record differentiates us and proves our leadership in numerous promising sectors like property and growth companies.
Consisting of 13 different profiles (pharmacist, engineer, financier, etc), the DNA of our financial analysis office is value added and sector expertise. Through daily monitoring and detailed analyses of companies and sectors, we seek to provide a differentiating vision of our 120 stocks followed. Our ideas are circulated every day to nearly 1,000 professionals.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.